Citations

Clear

2853 citation(s) found for "Park, SH".

Early identification of rare disease using deep phenotyping of electronic health records
Tunstall, Tate, Ng, Pauline C, Meyers, Lindsay, Coldagelli, Maria-Renee, Yang, Lu, Pereira, Naveen, Osundiji, Mayowa, Im, Kate, Kumar, Akash , Rabinowitz, Matt, Tunstall, Tate, Ng, Pauline C. , Yang, Lu

Mayo Clinic

No container title available | September 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.11.26362811 Get It

Abstract Patients with rare genetic disorders often wait years for a correct diagnosis, highlighting the urgent need for early and efficient triage for those at risk. Electronic health records (EHRs) are rich in useful information, yet the extent to which this data is sufficient to generate prediagnostic signals is uncertain. We trained machine learning models on billing codes and phenotypes extracted from clinical notes and applied these across eight conditions in a longitudinal cohort of roughly 3 million patient records from the Mayo Clinic, seeking early identification of conditions. The number of patients identified early varied by condition, ranging from 10% to 89% at 99% specificity. Median lead times exceeded one year prior to the first diagnostic billing code for most conditions, including Fabry disease (1,408 days), hereditary angioedema (2,755 days), neurofibromatosis type 1 (1,067 days), and hereditary hemorrhagic telangiectasia (2,320 days). We show that ML models trained on EHR data can prioritize patients for clinician review and confirmatory genetic testing and that the integration of diverse phenotypic data sources provides superior predictive value.
Inter‐institutional perspectives on usage of fibrinogen replacement therapies in North America
Tay, Cindy , Stephens, Laura D. , Lu, Wen , O'Brien, Kerry , Tint, Hlaing , Eichbaum, Quentin , Stephens, Laura , Lu, Wen

Mayo Clinic

Vox Sanguinis | September 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/vox.70374 | PMID 42740597 Get It

Abstract Background and Objectives Cryoprecipitated antihemophilic factor (cryoprecipitate), fibrinogen concentrate (FC), and pathogen‐reduced cryoprecipitated fibrinogen complex (PR cryoprecipitate) are sources of fibrinogen replacement, and each has advantages and disadvantages in terms of cost, efficacy, safety, and logistics of administration. This study examines the respective utilization frequencies of these different products at institutions in North America and the factors influencing the decision on which one(s) to adopt. Materials and Methods A survey was distributed via email to contacts for Advancement of Blood and Biotherapies (AABB)‐accredited blood banks/transfusion services. Survey questions covered topics including the availability and usage of FC, cryoprecipitate, and PR cryoprecipitate, as well as the perceived advantages of each product. Results A total of 53 responses were received from surveyed institutions (estimated 25% response rate). Over half (31/53, 58.5%) of respondents exclusively used cryoprecipitate, 30.2% (16/53) used two sources of fibrinogen replacement, and 7.5% (4/53) used all three (cryoprecipitate, FC, and PR cryoprecipitate). More than half of the institutions restricted FC to specific indications, primarily for cost containment. The most commonly cited advantages of FC over cryoprecipitate were storage convenience and rapid reconstitution. Conclusion Surveyed institutions in the United States and Canada primarily use cryoprecipitate for fibrinogen replacement, with variable usage of FC and limited usage of PR cryoprecipitate. The perception of FC being more expensive than cryoprecipitate predominated. Further studies comparing available fibrinogen replacement options would be valuable, particularly with consideration of product acquisition cost, wastage, impacts on utilization of other blood products, and patient outcomes.
Temporal EHR Models Detect Rare Disease Years Before Diagnosis
Yang, Lu, Ng, Pauline, Lun, Ming Yin, Tunstall, Tate, Meyers, Lindsay, Osundiji, Mayowa, Im, Kate, Lavertu, Adam , Rabinowitz, Matt, Tunstall, Tate, Kumar, Akash

Mayo Clinic

No container title available | September 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.10.26362561 Get It

Background. Rare diseases collectively affect an estimated 300 million people worldwide, yet patients wait an average of 4-8 years for a correct diagnosis after visiting multiple physicians, accumulating unexplained findings, and suffering preventable disease progression before a unifying diagnosis is reached. Electronic health records (EHRs) capture this pre-diagnostic trajectory in rich detail, but conventional methods typically collapse years of longitudinal phenotypic signals into a single static snapshot; our approach instead models this temporal structure directly. Methods. We conducted a retrospective cohort study using longitudinal EHR data from approximately 3 million patients at Mayo Clinic Platform_Accelerate. Cases were patients with confirmed diagnoses of 10 rare diseases; controls (~5,200 per disease) had no record of any rare disease. HPO phenotype terms were extracted from clinical notes and laboratory results using a medspaCy NLP pipeline; ICD codes were grouped at three-character level. We developed and trained two temporal models, GRU-Attn and Conformer, that encode patient histories as quarterly time-binned sequences spanning up to 30 years, and compared these against three static baselines (CatBoost, XGBoost, logistic regression). Models were evaluated systematically at prediction horizons h = 1-10 years before diagnosis. Results. In the full held-out cohort benchmark, temporal models outperformed static baselines across the large majority of diseases and prediction horizons, with the advantage widening substantially as the horizon lengthened. At 1-2 years prior to diagnosis, mean AUROC was 0.928 (GRU-Attn) versus 0.871 (CatBoost); at 6-10 years prior to diagnosis, 0.726 versus 0.693, with static models degrading to near-chance for some diseases. Combining HPO and ICD features yielded the strongest performance, with a mean gain of +0.063 AUROC over the best single source at 1-2 years prior to diagnosis. Separately, in a manually curated cohort of 143 confirmed-undiagnosed cases with extended EHR histories, GRU-Attn identified 138 cases before first disease mention and all 143 cases before formal diagnosis at the prespecified 99th-percentile specificity threshold, with median lead times of 1.1-8.3 years and 1.9-21.7 years, respectively. Conclusions. By learning from the temporal trajectory of phenotypic signals rather than their static aggregate, temporal EHR models improved retrospective early detection performance across several rare diseases, most powerfully for conditions where pre-diagnostic findings accrue gradually and heterogeneously over years. These results show that longitudinal EHR trajectories carry rare-disease signal beyond static phenotypic burden and support prospective evaluation of temporal EHR modeling for rare-disease risk stratification.
Recent advancements in gynecologic cancer research: a SPORE investigators meeting report
Curtis, Marion , Benbrook, Doris M. , Kanakkanthara, Arun , Curtis, Marion , Levinson, Kimberly L. , Kannan, Nagarajan , Hannafon, Bethany N. , Kozbor, Danuta , Chandra, Vishal, Hempel, Nadine , Leslie, Kimberly Kay , Liang, Han, Powell, M. A., Rai, Rajani , Steinkamp, Mara P. , Xue, Xiang

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnci/djag319 | PMID 42745474 Get It

Abstract Global incidence and mortality rates for endometrial and cervical cancers have been steadily rising, while these rates for ovarian cancer have decreased. Although these cancers represent unique diseases and challenges, overlapping biology and responses to targeted and immunotherapies create opportunities to advance research through shared knowledge and resources. In 2025, investigators funded by National Cancer Institute (NCI) Specialized Programs of Research Excellence (SPORE) and other NCI-supported grants convened a hybrid meeting to identify challenges and knowledge gaps in translational research, highlight advances, define shareable resources and technologies, and foster collaboration among the Gynecologic Cancer SPORE sites, patient advocates, and NCI staff. Special sessions were arranged for presentations by Patient Advocates, Early-stage Investigators, Investigators Transitioning to Gynecologic Cancer Research. Meeting-wide workshops on Sharing Resources and Reducing Time to Activation of Clinical Trials and networking events were included. Collectively, the presentations converged on three overarching themes: (i) interception and early disease biology, (ii) development of innovative targeted and immune-based therapies, (iii) critical role of shared resources and collaborative infrastructure in accelerating translational progress. The unifying theme across disease sites was molecular advances to improve early detection/prevention and to drive therapeutic advancements. Novel findings discussed included: candidate precursor cells and mechanisms of high grade serous ovarian cancer development; therapeutic vaccines and their delivery methods for cervical dysplasia; identification of immune-targetable ovarian cancer antigens; various novel molecularly targeted drugs and immune-based agents for endometrial and ovarian cancers; and approaches to bypass drug resistance. Workshops delineated actionable strategies to further advance gynecologic cancer translational research.
From Housing to Hotspots: Integrating a Housing-Based Measure of Individual Socioeconomic Status with Geospatial Analysis to Target Colorectal Cancer Screening in Rural Communities
Yao, Rebecca , Beenken, Madison, Watson, Dave , Wheeler, Philip H., Finch, Mike, Kelleher, Dan , Anil, Gokhan , Anderson, Trent, Madden, Kathy A., Okuno, Scott H. , Odedina, Folakemi T., Park, Eunice , Dugani, Sagar B., Sosso, Jessica , Sabarish, Shivani , Singh, Gurpreet, Lugo-Fagundo, Nahyr, Kim, W. Ray, Walker-Mcgill, Cheryl L., Juhn, Young J. , Lynch, Brian , Wi, Chung‐Il , Madden, Kathy A., Westfall, Erin , Sharma, Pravesh , Dugani, Sagar B. , Foss, Randy , Hidaka, Brandon H. , Singh, Gurpreet, Howick V, James F , Calvin, Andrew D. , Walker-McGill, Cheryl Lynn, Rennert, Lior , Cerhan, James R. , Beenken, Madison J, Kelleher, Dan P., Westfall, Erin C, Park, Eunice Y., Sharma, Pravesh , Foss, Randy M, Sosso, Jessica L

Mayo Clinic

No container title available | September 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.28.26361444 | PMID 42922856 Get It

ABSTRACT Purpose This study assesses the association between colorectal cancer (CRC) screening and a validated, housing-based measure of individual-level socioeconomic status (SES, called HOUSES hereafter) within rural communities and determines whether HOUSES-integrated geospatial analysis can be used to tailor interventions. Methods We used CRC screening data from a subset of Mayo Clinic Midwest patients living in cities without ready access to routine care in the Mayo Clinic Health System in 2019 to represent rural communities. At the individual level, we assessed the association between CRC screening rates and the HOUSES index, adjusting for age, sex, race/ethnicity, comorbidity, distance from home address to clinic, and area deprivation index, using a multilevel mixed-effects logistic regression model. Additionally, we conducted geospatial analysis to examine the correlation between hotspots of 1) lower CRC screening rates and 2) lower SES of the subject population (HOUSES quartile 1). Findings Among 34,489 individuals (median age 64.0 years, 52.4% female), those with the lowest SES (HOUSES Q1) had 37% lower odds of being CRC screening adherent than those with the highest SES (HOUSES Q4) (adj. OR [95% CI]: 0.63 [0.58-0.69]). In the 14 identified HOUSES Q1 hotspots, there was a significant correlation in counts of HOUSES Q1 and low CRC screening (correlation coefficient=0.81). Conclusion Lower SES was significantly associated with lower CRC screening among rural populations. HOUSES-enabled geospatial analysis identified geographic hotspots with lower CRC screening rates for targeted interventions to address disparities in CRC screening in rural communities. HOUSES may be a useful digital tool for cancer preventive care and research.
The VPS35 p.A320V variant segregates with Parkinson's disease in a pesticide-exposed family
Glendinning, S. G. , Gonzalez, Jose Matias Arbelo , Díaz-Feliz, Lola , Zamora, Rocio Malo de Molina, Sanchez-Reyes, Alexia Teresa , Su, Kimmy , Cole, D. J., Hsieh, F. , Ross, Owen A. , (GP2), Global Parkinson's Genetics Program, Initiative, Veterans Parkinson's Disease Genetics, Ross, Owen A , Glendinning, Sophie , Zamor, Rocio Malo de Molina, Gomes, Sara , Soto‐Beasley, Alexandra I. , Wszołek, Zbigniew K. , Kim, Han‐Joon , Shin, Jung Hwan , Lim, Shen‐Yang , Tan, Ai Huey , Ahmad‐Annuar, Azlina , Tay, Yi Wen , Kleinz, Teresa , Klein, Christine , Alessi, Dario R. , Zimprich, Alexander , Pástor, Pau , Sammler, Esther , (GP2), Global Parkinson s Genetic Program, Zabetian, Cyrus P. , Lorenzo‐Betancor, Oswaldo

Mayo Clinic

No container title available | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.21.26358613 Get It

Background. The VPS35 p.D620N variant causes autosomal dominant Parkinson's disease (PD) and has been shown to activate the LRRK2 kinase pathway, resulting in increased Rab substrate phosphorylation in peripheral immune cells and elevated urinary bis(monoacylglycero)phosphate (BMP) levels. Recently, a VPS35 variant of unknown significance (c.959C>T; p.A320V) was described in two late-onset sporadic PD patients. Methods. We ascertained a family from the Canary Islands in which six siblings were chronically exposed to high doses of pesticides. Three siblings developed levodopa-responsive, akinetic-rigid PD, while the other three remained unaffected. Whole-exome sequencing was performed in the three affected siblings. The frequency of the resulting candidate variant was assessed in 23,327 PD patients and 9,235 controls from four independent cohorts. Members of this pedigree and unrelated controls were assessed for LRRK2 kinase activity in monocytes and neutrophils and BMP levels in urine. Results. The three affected siblings were all heterozygous for p.A320V, whereas the three unaffected siblings did not carry the variant. In the combined PD case-control cohort, p.A320V was identified in six patients and one control. However, unlike p.D620N, heterozygous carrier status for p.A320V was not associated with increased LRRK2 kinase activity or elevated urine BMP levels. Conclusions. While VPS35 p.A320V co-segregated with PD in this family, it did not exhibit the characteristic LRRK2-associated biomarker signature observed in VPS35 p.D620N carriers. It is possible that p.A320V exerts a subtle effect on VPS35 function that was not captured by the assays performed and that chronic pesticide exposure contributed to disease penetrance in this pedigree.
Validation of the Semi-Quantitative MRI (SQ-MRI) Score as a Biomarker for Non-Calcific Chronic Pancreatitis in a Multicenter Cohort
Tirkes, Temel, Chang, Stephanie T., Mawad, Kareem , Shah, Zarine K. , Venkatesh, Sudhakar K., Wachsman, Ashley, Li, Liang, Li, Shuang, Easler, Jeffrey, Fogel, Evan L. , Forsmark, Christopher E. , Hart, Phil A., Pandol, Stephen J., Park, Walter G., Topazian, Mark, Trikudanathan, Guru, Vege, Santhi Swaroop, Conwell, Darwin L., Yadav, Dhiraj, Tirkes, Temel , Dasyam, Anil K. , Spilseth, Benjamin , Takahashi, Naoki , Venkatesh, Sudhakar K. , Easler, Jeffrey J. , Forsmark, Chris E. , Hart, Phil A. , Pandol, Stephen J , Park, Walter G., Trikudanathan, Guru , Van Den Eeden, Stephen K , Vege, Santhi Swaroop , Conwell, Darwin L. , Yadav, Dhiraj

Mayo Clinic

No container title available | August 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10504233/v1 Get It

Abstract Purpose Validate the semiquantitative (SQ)-MRI score for chronic pancreatitis (CP) diagnosis in an independent, multicenter cohort. Methods We analyzed MRIs performed at baseline in 337 participants with acute (AP) or recurrent AP (RAP) and 67 with non-calcific chronic pancreatitis (NCCP) enrolled in the PROCEED study from 6/2017 to 3/2023. MRIs were performed at multiple clinical centers using site-specific clinical protocols and a variety of MRI vendors to evaluate the SQ-MRI score in a real-world setting. The SQ-MRI score was calculated using the T1 signal intensity ratio of the pancreas to the spleen (T1 score), arteriovenous enhancement ratio (AVR), and pancreatic body diameter (PBD). We adjusted for confounding by participant characteristics via propensity score weighting. Results Median AVR was higher in AP/RAP (1.18, IQR: 0.97–1.44) than in the NCCP group (1.03, IQR: 0.78–1.22, p = 0.007). Pancreatic body diameters were larger in AP/RAP than in the NCCP group − 7–14 mm (10% vs 25%), 14–20 mm (40% vs 54%), and > 20 mm (50% vs 21%), respectively ( p < 0.01). Median T1 score was higher in AP/RAP (1.18, IQR: 0.96–1.40) than in the NCCP group (1.04, IQR: 0.86–1.32, p = 0.10). Median SQ-MRI score in the AP/RAP group was significantly lower, 1.91 (IQR: 0.97, 2.95), than in the NCCP group, 2.74 (IQR: 2.04–4.03) ( p < 0.001). The propensity score-adjusted AUC for SQ-MRI to distinguish AP/RAP from NCCP was 0.64, which was higher than for individual parameters. Conclusion We have validated the SQ-MRI score in a multicenter cohort using an independent, real-world MRI dataset.
NCCN Guidelines® Insights: Survivorship, Version 3.2026
Peterson, L., McDonough, Allison L. , Ansbaugh, Shannon M., Heredia, Ella J. Ariza, Armenian, Saro, Baker, K. Scott, Cathcart-Rake, Elizabeth J., Cohen, Stuart H. , Fairman, Nathan, Feliciano, Josephine, Flores, Tessa , Gabel, Nicolette , Hill‐Kayser, Christine E. , Hock, Karen, Kline-Quiroz, Cristina, Lee, Nita K., Mooney, Kathi, Moryl, Natalie , Neuman, Heather, Overholser, Linda, Patel, Chirayu G. , Porpiglia, Andrea, Saidain, Ava, Schapira, Lidia , Smith, Sophia K., Tenner, Laura, Ah, Diane Von , Zee, Phyllis, Freedman-Cass, Deborah, McMillian, Nicole, Ariza‐Heredia, Ella , Armenian, Saro H. , Ballinger, Tarah Jean , Cathcart-Rake, Elizabeth , Day, Andrew T. , Evgeniou, Evgenios , Feliciano, Josephine , Friedman, Debra L. , Hock, Karen , Kline‐Quiroz, Cristina , Moore, Halle C. F. , Neuman, Heather B. , Overholser, Linda , Porpiglia, Andrea S., Rogers, Laura Q. , Yang, Eric H. , Freedman-Cass, Deborah A., McMillian, Nicole R.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 17, 2026 | Volume: 24 | Issue: 8 | Pages: No page available

10.6004/jnccn.2026.0039 | PMID 42607712 Get It

The NCCN Guidelines for Survivorship offer guidance for health care providers who care for survivors of adult-onset cancer. These guidelines include screening, evaluation, and treatment recommendations for common physical and psychosocial problems resulting from cancer and its treatment and provide a framework for care coordination. They also present guidance for helping cancer survivors to enhance their wellness and maintain a healthy lifestyle. This article summarizes the panel’s current recommendations and recent updates regarding anxiety, depression, distress, and trauma in cancer survivors.
Mesothelioma: Pleural, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology
Stevenson, James, Riely, Gregory J. , Wood, Douglas E. , Aisner, Dara L. , Bauman, Jessica R., Chang, Joe Y., Desai, Aakash, Dilling, Thomas J. , Dowell, Jonathan, Durm, Gregory A. , Gettinger, S., Grotz, Travis E., Gubens, Matthew A., Lackner, Rudy P., Lanuti, Michael, Levy, Benjamin, Loo, Billy W., Maldonado, Fabien, Morgensztern, Daniel , Mullikin, Trey C., Ng, Thomas, Owen, Dawn , Owen, Dwight H., Patil, Tejas, Polanco, Patricio M., Riess, Jonathan, Mendez, Ana Lucia Ruano, Shapiro, Theresa A. , Singh, Aditi P., Tam, Alda, Yau, Edwin, Yun, Karen, Gregory, Kristina, Hang, Lisa, Desai, Aakash , Desai, Aakash P , Axtell, Andrea L. , Bauman, Jessica R. , Bharat, Ankit , Gettinger, Scott , Grotz, Travis E. , Gubens, Matthew A. , Juloori, Aditya , Levy, Benjamin , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Maldonado, Fabien , Mullikin, Trey C. , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane , Yau, Edwin , Yun, Karen M. , Gregory, Kristina M., Hang, Lisa E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 17, 2026 | Volume: 24 | Issue: 8 | Pages: No page available

10.6004/jnccn.2026.0038 | PMID 42607715 Get It

Mesothelioma is a rare cancer that originates from the mesothelial surfaces of certain sites within the body. Pleural mesothelioma is the most common type and represents approximately 85% of mesotheliomas. The NCCN Guidelines for Mesothelioma: Pleural provide recommendations for evaluation and treatment in patients with pleural mesothelioma. The NCCN Guidelines will continue to be updated annually based on available clinical evidence and panel consensus.
Current Knowledge and Gaps in Geriatric Rehabilitation among Physical and Rehabilitation Medicine specialists
Capodaglio, Paolo , Antoniadou, Eleftheria , Oh‐Park, Mooyeon , Frontera, Walter R, Terzic, Carmen M., Ambrose, Anne Felicia , Pola, Marta Supervía, Kutsal, Yesim Gokce, Strasser, Dale C., Bean, Jonathan F. , Seijas, Vanessa , Lim, Jae-Young, Frontera, Walter R. , Han, Der‐Sheng , Gimigliano, Francesca , Kutsal, Yeşim Gökçe, Nguyen, Vu Q. C.

Mayo Clinic

Annals of Geriatric Medicine and Research | August 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.4235/agmr.26.0149 | PMID 42581575 Get It